Receptor-selective retinoids for psoriasis: focus on tazarotene.

@article{Weindl2006ReceptorselectiveRF,
  title={Receptor-selective retinoids for psoriasis: focus on tazarotene.},
  author={G{\"u}nther Weindl and Alexander R{\"o}der and Monika Sch{\"a}fer-Korting and Martin Schaller and Hans Christian Korting},
  journal={American journal of clinical dermatology},
  year={2006},
  volume={7 2},
  pages={85-97}
}
Topical and oral retinoids have been successfully used in antipsoriatic therapy over the last 50 years. Development of more selective agents has led to an improved efficacy and safety profile. The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene. Topical tazarotene displays an onset of action and efficacy similar to those of other established antipsoriatic agents. Common adverse events of this agent such as pruritus, burning, local… CONTINUE READING